Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844090 | 0.80 | KMT2A (0.33) | KDM4EKMT2APOLB | |
| SCHEMBL3652178 | 0.76 | ALDH1A1 (0.38) | KDM4EKMT2AALDH1A1OPRM1OPRL1 | |
| SCHEMBL3756826 | 0.76 | ALDH1A1 (0.38) | KDM4EKMT2AALDH1A1OPRM1OPRL1 | |
| SCHEMBL2752263 | 0.75 | ALDH1A1 (0.39) | KMT2AALDH1A1 | |
| SCHEMBL27466489 | 0.75 | CCR5 (0.36) | KMT2AOPRM1OPRL1 | |
| SCHEMBL4551091 | 0.74 | KMT2A (0.45) | KMT2AHPGDALDH1A1POLBCYP2C19 | |
| SCHEMBL1515302 | 0.74 | GRIN1 (0.37) | KMT2AOPRM1OPRL1 | |
| SCHEMBL6496554 | 0.74 | GRIN1 (0.37) | KMT2AOPRM1OPRL1 | |
| SCHEMBL633802 | 0.74 | GRIN1 (0.37) | KMT2AOPRM1OPRL1 | |
| SCHEMBL10862803 | 0.74 | OPRM1 (0.33) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249111-A1 | Piperdine Derivatives as CCR5 Inhibitors | NOVARTIS AG | 2008-10-09 | — | — | US | disclosed |
| US-7399771-B2 | Piperidine derivatives as CCR5 inhibitors | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249111-A1 | Piperdine Derivatives as CCR5 Inhibitors | CCR5, CCR2, CCR1 | KDM4E 4680/4885KMT2A 4091/4885HPGD 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.